Scrip
US FDA panel rejects maintenance use of OSI/Roche's Tarceva
17 December 2009
Sue Sutter
The US
FDA's oncologic drugs advisory panel has rejected a maintenance indication for
OSI Pharmaceuticals/
Roche's EGFR-targeted small molecule drug Tarceva (erlotinib) in non-small cell lung cancer (NSCLC).
By a 12 to one vote, the panel recommended against approval for maintenance treatment...
Please Login to read the full article.
17 December 2009
Sue Sutter
By a 12 to one vote, the panel recommended against approval for maintenance treatment...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
